Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Type I interferons are important in the defense of viral infections. Recently, neutralizing IgG auto-antibodies against type I interferons were found in patients with severe COVID-19 infection. Here, we analyzed expression of CD169/SIGLEC1, a well described downstream molecule in interferon signaling, and found increased monocytic CD169/SIGLEC1 expression levels in patients with mild, acute COVID-19, compared to patients with severe disease. We recommend further clinical studies to evaluate the value of CD169/SIGLEC1 expression in patients with COVID-19 with or without auto-antibodies against type I interferons.
【저자키워드】 COVID-19, SARS-CoV-2, type I interferons, CD169, SIGLEC1, 【초록키워드】 IgG, Coronavirus disease 2019, coronavirus, Infection, interferon, viral infections, type I interferon, Patient, Mild, interferon signaling, Neutralizing, expression, clinical study, severe disease, Severe COVID-19 Infection, acute respiratory syndrome, expression level, acute COVID-19, Defense, downstream, described, analyzed, evaluate, caused, Type, auto-antibody, patients with COVID-19, 【제목키워드】 disease severity, expression level, expressed, circulating monocyte,